A first in patient Phase I II clinical study to investigate the safety and efficacy of genome edited hematopoietic stem and progenitor cells in subjects with severe complications of sickle cell disease

Gender
Any

Age Group
Any

At a Glance

IRB#IRB20-0235

Lead PhysicianJames L. LaBelle

Collaborator(s)N/A

EligibilityRecruiting